T Cell Activation by Lipopeptide AntigensD. Branch Moody, Michael B. Brenner, Ian A. Wilson et al.|Science|2004Cited by 262
Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosisAnindit Chhibber, David C. Young, Alexandre H. Watanabe et al.|Journal of Cystic Fibrosis|2024Cited by 4
P250 Minimum inhibitory concentration targeted antibiotic dose optimization in patients with cystic fibrosisDavid C. Young, Theodore G. Liou, Zubin Bhakta et al.|Journal of Cystic Fibrosis|2023Cited by 0
A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosisS. Sherwood, David C. Young, Casey Tak et al.|Pediatric Pulmonology|2024Cited by 0
P150 Impact of adverse effects on CFTR modulator dosing in people with cystic fibrosis (PwCF)E. Chang, H. R. D. Jacobs, David C. Young et al.|Journal of Cystic Fibrosis|2024Cited by 0